PCF Science

Apply to join our PCF Science Team! 👇

LBA1/Plenary #ASCO26: PROTEUS trial Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage ! @DanaFarber @DanaFarber_GU @ASCO @OncoAlert

At #AACR26, @AndreaMiyahira caught up with PCF Investigator @VanAllenLab to congratulate him on winning the AACR-Wuan Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Watch to learn more.

Celebrating the next generation of researchers at the @AACR Annual Meeting! @AndreaMiyahira joined the 2026 recipients of the PCF Scholar-in-Training Awards, recognizing outstanding early-career scientists presenting impactful work in prostate cancer. #AACR26

PROX1 explored as a driver of neuroendocrine #ProstateCancer progression. @Bajji @DanaFarber joins @AndreaMiyahira @PCFnews in discussing #PROX1 as an epigenetically derepressed driver in neuroendocrine prostate cancer. #WatchNow on UroToday > bit.ly/47kzVEk

Targeting the regulator PTGES3 to suppress androgen receptor in resistant #ProstateCancer. Haolong Li, PhD @fredhutch joins @AndreaMiyahira @PCFnews to presents genome-scale CRISPRi screening using an endogenous AR reporter that identified PTGES3 as a top androgen receptor regulator. #WatchNow > bit.ly/3NGsFfo

Investigational all-in-one CAR T-cell platform for #ProstateCancer. @NourShobaki @PennMedicine joins @zklaassen_md @GACancerCenter to discuss an all-in-one CAR T platform targeting STEAP2, engineered to secrete PSMA CD28 bispecifics at tumor sites and resist TGF-β–mediated immunosuppression—promising preclinical leads now advancing toward IND-enabling studies. #WatchNow > bit.ly/3M3hlcm

Prof @MatthiasEiber from @TU_Muenchen is one of the PSMA PET/CT and Theranostics PIONEERS. Come and hear his insights from almost 15 years of PSMA experience at ProsTIC26: Case by Case Theranostics, September 3-5 in Melbourne, Australia. Find out more, and register before places run out: prostic26.org We have invited speakers from medical oncology, urology, radiation oncology, nuclear medicine, radiopharmaceutical sciences and industry. @pros_tic @PCF_Science

Clink link to article in European Urology. PSMA total tumour volume at 3months predicts overall survival independent of treatment in ENZAp. This raises important questions about how we should be measuring progression on PSMA. @ANZUPtrials @PCF_Science authors.elsevier.com/a/1mv8014kpm4a…

Safety and dosing of lutetium-PSMA in the pre-chemotherapy #PSMAfore trial. Oliver Sartor, MD @EJHospital sits down with @zklaassen_md @GACancerCenter reviewing PSMAfore safety data showing lutetium PSMA-617 is better tolerated in chemo‑naïve mCRPC than in the heavily pretreated VISION cohort, with fewer AEs and cytopenias. Standard dosing is 7.4 GBq q6w × 6, but he stresses tailoring to bone disease burden, confirming PSMA PET positivity, and checking counts/renal function—especially as many patients now prefer #Pluvicto over chemotherapy. #WatchNow > bit.ly/3OAiOYt @PCFnews @PCF_Science

We may never be able to redo the TOAD trial, but this should at least give us some pause before assuming that early hormonal tx saves lives. Similar observational work: ascopubs.org/doi/abs/10.120… Congrats to @jonnatansheila & team for this practice-informing work! @PCF_Science

While it is becoming trendy to start tx for advanced PCa @ BCR, earlier tx can mean earlier tx-resistance. We studied PCa kinetics longitudinally to find that CRPC is associated w disease acceleration, which has potential to shorten OS of pts w early tx 🧵 onlinelibrary.wiley.com/doi/full/10.10…

Ever wonder how toggling protein synthesis impacts cellular identity? Dr. Rashmi Mishra @HsiehLab did and through a clever drug screen discovered that the cap-binding domain of eIF4E regulates lineage fate in prostate cancer. Story hit newsstands today: jci.org/articles/view/…

Should be a great meeting & @theNCI will be well represented Dr. Pete Choyke @PChoyke will discuss the role of #PSMA in the clinic Dr. Melissa Abel @melissaabel20 will present new data on the clinical significance of local findings on #PSMA in post-salvage #BCR #ProstateCancer

After 28 years of visionary leadership, @soulehoward1 is retiring from PCF. His work has transformed treatments & impacted countless patients. We’re excited to welcome VP of Global Research & Innovation @AndreaMiyahira as we continue driving progress in prostate cancer research.

Today, we partnered with @NBAalumni for a health fair and screening event as part of our #CheckTheBox campaign where we are raising awareness about the power of early detection with a simple PSA blood test. Learn more about prostate cancer screening: bit.ly/4cvZTrL

PCF is proud to award $6.3 million to the next generation of #prostatecancer researchers whose innovative work could drive breakthroughs in prostate cancer detection, treatment and care. Learn more about this year’s Young Investigator Awards: bit.ly/3OwhbLr #meded

Safety and dosing of lutetium-PSMA in the pre-chemotherapy #PSMAfore trial. Oliver Sartor, MD @EJHospital sits down with @zklaassen_md @GACancerCenter reviewing PSMAfore safety data showing lutetium PSMA-617 is better tolerated in chemo‑naïve mCRPC than in the heavily pretreated VISION cohort, with fewer AEs and cytopenias. Standard dosing is 7.4 GBq q6w × 6, but he stresses tailoring to bone disease burden, confirming PSMA PET positivity, and checking counts/renal function—especially as many patients now prefer #Pluvicto over chemotherapy. #WatchNow > bit.ly/3OAiOYt @PCFnews @PCF_Science

With @asco #GU26 approaching one key bit of data missing in the context of #PSMA+ #BCR #ProstateCancer management in the wake of the #EMBARK data is how does #PSA Doubling Time interface w/ #PSMA Pet findings. Dr. Melissa Abel @melissaabel20 @theNCI will share this data @ #GU26

New team picture @VHIO #prostatecancer #proudPI. Thanks to @criscancer @SaludISCIII @ContraCancerEs @FundacionFero @CDMRP @PCF_Science for supporting our group’s research!

1/11 Excited to share our study of polyamines in prostate cancer in @CR_AACR! We found that, in models of advanced PCa, supraphysiological androgens (SPA) drive production of polyamines that help the cancer survive. @PCF_Science @AACR @hopkinskimmel aacrjournals.org/cancerres/arti…